查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1596747

無菌注射劑市場：按分子類型、藥物、適應症、分佈分類 - 全球預測 2025-2030

Sterile Injectable Drugs Market by Molecule Type (Large Molecule, Small Molecule), Drug (Blood Factors, Cytokines, Immunoglobulins), Indication, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年無菌注射劑市值為5,184.9億美元，預計2024年將達到5,686.2億美元，複合年成長率為10.17%，到2030年將達到1,2181億美元。

無菌注射劑是重要的藥品，其設計不含活微生物，可確保經由腸胃外途徑安全給藥。這種需求源於快速有效地提供治療的至關重要性，特別是在需要即時藥物行動的情況下，例如緊急情況和手術。應用涵蓋多種治療領域，包括癌症、心血管疾病和感染疾病，最終用途主要在醫院、診所和門診手術中心。市場成長的關鍵因素是慢性病的增加、生技藥品的進步、藥物傳遞系統的創新。向生物相似藥的轉變以及對客製化治療的需求不斷增加也增加了機會。對救生藥物的監管支持也將提供進一步的推動力。然而，市場拓展面臨嚴格法律規範、高製造成本、複雜製造流程等挑戰。供應鏈中斷和與低溫運輸要求相關的複雜物流進一步限制了成長。潛在的機會在於利用生技藥品和標靶治療的進步以及採用一次性系統和連續生物加工等創新製造技術來提高效率並降低成本。策略建議包括投資研發以提高藥物穩定性和保存期限，以及尋求夥伴關係以擴大市場。市場競爭的特徵是大量的研究投入和嚴格的監管合規，要求企業專注於創新。智慧標籤和防篡改功能等包裝創新標誌著差異化之路。最終，無菌注射劑市場具有強大的成長潛力，但必須策略性地應對監管挑戰和供應鏈複雜性，以有效利用其中的新機會。平衡成本效率和高品質生產通訊協定被認為是維持業務成長和實現市場目標的關鍵。

主要市場統計
基準年[2023] 5184.9億美元
預測年份 [2024] 5686.2億美元
預測年份 [2030] 12,181億美元
複合年成長率（%） 10.17%

市場動態：揭示快速發展的無菌注射劑市場的關鍵市場洞察

供需的動態交互作用正在改變無菌注射劑市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 人口中慢性病盛行率增加
    • 無菌注射劑的巨大好處和有效性
    • 增加醫療支出和改善醫療設施
  • 市場限制因素
    • 無菌注射藥物生產高成本
  • 市場機會
    • 新配方和遞送方法的開發
    • 擴建無菌注射藥品生產設施
  • 市場問題
    • 嚴格的核准和認證流程

波特五力：駕馭無菌注射劑市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢、解決弱點並避免潛在的挑戰，以確保更強大的市場地位。

PESTLE分析：了解無菌注射劑市場的外部影響

外部宏觀環境因素在塑造無菌注射劑市場的表現動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析：了解無菌注射藥物市場的競爭格局

對無菌注射劑市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：無菌注射劑市場供應商的績效評估

FPNV定位矩陣是評估無菌注射劑市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：規劃無菌注射劑市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對無菌注射劑市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1.市場滲透率：對當前市場環境的詳細審查，主要企業的廣泛資料，評估他們在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 人口中慢性病盛行率增加
      • 無菌注射劑的巨大好處和有效性
      • 醫療費用增加和醫療設施改善
    • 抑制因素
      • 製造無菌注射藥物的高成本
    • 機會
      • 新製劑和給藥方法的開發
      • 擴建無菌注射藥品生產設施
    • 任務
      • 嚴格的核准和認證流程
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章無菌注射劑市場：依分子類型

  • 介紹
  • 高分子
  • 小分子

第7章 無菌注射劑市場：依藥物分類

  • 介紹
  • 血液因素
  • 細胞激素
  • 免疫球蛋白
  • 胰島素
  • 單株抗體 (mAb)
  • 肽激素
  • 疫苗

第8章無菌注射劑市場：依適應症分類

  • 介紹
  • 自體免疫疾病
  • 心血管和代謝疾病
  • 胃腸病學
  • 血液學
  • 感染疾病
  • 神經病學
  • 腫瘤學

第9章無菌注射劑市場：依分佈

  • 介紹
  • 電子商務
  • 醫院藥房
  • 零售藥房

第10章美洲無菌注射劑市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區無菌注射劑市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的無菌注射劑市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Adare Pharma Solutions
  • Aenova Group
  • Almac Group
  • Avara Pharmaceutical Services, Inc.
  • Baxter International Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • CordenPharma
  • Eli Lilly and Company
  • Evonik Industries AG
  • F. Hoffmann-La Roche Ltd
  • FAMAR Health Care Services
  • Fresenius Kabi Ag
  • Grifols SA
  • Hikma Pharmaceuticals PLC
  • Jubilant Pharmova Limited
  • Lonza
  • Nexus Pharmaceuticals, Inc.
  • Patheon, Inc.（Thermo Fischer）
  • Pfizer Inc.
  • Recipharm AB
  • Siegfried Holding AG
Product Code: MRR-F6513A06BE96

The Sterile Injectable Drugs Market was valued at USD 518.49 billion in 2023, expected to reach USD 568.62 billion in 2024, and is projected to grow at a CAGR of 10.17%, to USD 1,021.81 billion by 2030.

Sterile injectable drugs are crucial pharmaceutical products designed to be free from viable microorganisms, ensuring safe administration via parenteral routes. Their necessity stems from the critical need for rapid and efficient delivery of therapeutic agents, particularly in settings requiring immediate drug action, such as emergencies and surgeries. Applications span across various therapeutic domains, including oncology, cardiovascular diseases, and infectious diseases, with their end-use predominantly in hospitals, clinics, and ambulatory surgical centers. Market growth is primarily driven by increasing prevalence of chronic diseases, advancements in biologics, and innovation in drug delivery systems. The shift towards biosimilars and the growing demand for customized therapies also enhance opportunities. Regulatory support for life-saving medications provides an additional boost. However, market expansion faces challenges such as stringent regulatory frameworks, high costs of production, and complex manufacturing processes. Supply chain disruptions and the intricate logistics associated with cold chain requirements further constrain growth. Potential opportunities lie in leveraging advancements in biologic drugs and targeted therapies, as well as in adopting innovative manufacturing technologies like single-use systems and continuous bioprocessing to improve efficiency and reduce costs. Investing in R&D to enhance drug stability and shelf-life and exploring partnerships for market expansion stand as strategic recommendations. The competitive nature of the market, characterized by significant research investments and strict regulatory adherence, demands that companies focus on innovation. Innovations in packaging, such as smart labeling and tamper-evident features, offer avenues for differentiation. Ultimately, the sterile injectable drugs market, while marked by robust growth potential, requires strategic navigation of regulatory challenges and supply chain complexities to capitalize on emerging opportunities effectively. Balancing cost-efficiency with high-quality production protocols will be key to sustaining business growth and achieving market objectives.

KEY MARKET STATISTICS
Base Year [2023] USD 518.49 billion
Estimated Year [2024] USD 568.62 billion
Forecast Year [2030] USD 1,021.81 billion
CAGR (%) 10.17%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Sterile Injectable Drugs Market

The Sterile Injectable Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of chronic diseases among population
    • Significant benefits and efficacy of sterile injectable drugs
    • Rise in healthcare spending and improved healthcare facilities
  • Market Restraints
    • High costs associated with sterile injectable drug manufacturing
  • Market Opportunities
    • Development of novel formulations and delivery methods
    • Growing expansion of sterile injectable drug manufacturing facilities
  • Market Challenges
    • Stringent approval and certification processes

Porter's Five Forces: A Strategic Tool for Navigating the Sterile Injectable Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Sterile Injectable Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Sterile Injectable Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Sterile Injectable Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Sterile Injectable Drugs Market

A detailed market share analysis in the Sterile Injectable Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Sterile Injectable Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Sterile Injectable Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Sterile Injectable Drugs Market

A strategic analysis of the Sterile Injectable Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Sterile Injectable Drugs Market, highlighting leading vendors and their innovative profiles. These include Adare Pharma Solutions, Aenova Group, Almac Group, Avara Pharmaceutical Services, Inc., Baxter International Inc., Boehringer Ingelheim International GmbH, Catalent, Inc., CordenPharma, Eli Lilly and Company, Evonik Industries AG, F. Hoffmann-La Roche Ltd, FAMAR Health Care Services, Fresenius Kabi Ag, Grifols S.A., Hikma Pharmaceuticals PLC, Jubilant Pharmova Limited, Lonza, Nexus Pharmaceuticals, Inc., Patheon, Inc. (Thermo Fischer), Pfizer Inc., Recipharm AB, and Siegfried Holding AG.

Market Segmentation & Coverage

This research report categorizes the Sterile Injectable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Molecule Type, market is studied across Large Molecule and Small Molecule.
  • Based on Drug, market is studied across Blood Factors, Cytokines, Immunoglobulins, Insulin, Monoclonal Antibodies (mAbs), Peptide Hormones, and Vaccine.
  • Based on Indication, market is studied across Autoimmune Diseases, Cardiovascular & Metabolic Diseases, Gastroenterology, Hematology, Infectious Diseases, Neurology, and Oncology.
  • Based on Distribution, market is studied across E-commerce, Hospital Pharmacy, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of chronic diseases among population
      • 5.1.1.2. Significant benefits and efficacy of sterile injectable drugs
      • 5.1.1.3. Rise in healthcare spending and improved healthcare facilities
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with sterile injectable drug manufacturing
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of novel formulations and delivery methods
      • 5.1.3.2. Growing expansion of sterile injectable drug manufacturing facilities
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent approval and certification processes
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Sterile Injectable Drugs Market, by Molecule Type

  • 6.1. Introduction
  • 6.2. Large Molecule
  • 6.3. Small Molecule

7. Sterile Injectable Drugs Market, by Drug

  • 7.1. Introduction
  • 7.2. Blood Factors
  • 7.3. Cytokines
  • 7.4. Immunoglobulins
  • 7.5. Insulin
  • 7.6. Monoclonal Antibodies (mAbs)
  • 7.7. Peptide Hormones
  • 7.8. Vaccine

8. Sterile Injectable Drugs Market, by Indication

  • 8.1. Introduction
  • 8.2. Autoimmune Diseases
  • 8.3. Cardiovascular & Metabolic Diseases
  • 8.4. Gastroenterology
  • 8.5. Hematology
  • 8.6. Infectious Diseases
  • 8.7. Neurology
  • 8.8. Oncology

9. Sterile Injectable Drugs Market, by Distribution

  • 9.1. Introduction
  • 9.2. E-commerce
  • 9.3. Hospital Pharmacy
  • 9.4. Retail Pharmacy

10. Americas Sterile Injectable Drugs Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Sterile Injectable Drugs Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Sterile Injectable Drugs Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Adare Pharma Solutions
  • 2. Aenova Group
  • 3. Almac Group
  • 4. Avara Pharmaceutical Services, Inc.
  • 5. Baxter International Inc.
  • 6. Boehringer Ingelheim International GmbH
  • 7. Catalent, Inc.
  • 8. CordenPharma
  • 9. Eli Lilly and Company
  • 10. Evonik Industries AG
  • 11. F. Hoffmann-La Roche Ltd
  • 12. FAMAR Health Care Services
  • 13. Fresenius Kabi Ag
  • 14. Grifols S.A.
  • 15. Hikma Pharmaceuticals PLC
  • 16. Jubilant Pharmova Limited
  • 17. Lonza
  • 18. Nexus Pharmaceuticals, Inc.
  • 19. Patheon, Inc. (Thermo Fischer)
  • 20. Pfizer Inc.
  • 21. Recipharm AB
  • 22. Siegfried Holding AG

LIST OF FIGURES

  • FIGURE 1. STERILE INJECTABLE DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. STERILE INJECTABLE DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. STERILE INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. STERILE INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. STERILE INJECTABLE DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. STERILE INJECTABLE DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES (MABS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY VACCINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY CARDIOVASCULAR & METABOLIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY E-COMMERCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL STERILE INJECTABLE DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 47. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES STERILE INJECTABLE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 56. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 58. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. AUSTRALIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. AUSTRALIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 63. AUSTRALIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. AUSTRALIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 65. CHINA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. CHINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 67. CHINA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. CHINA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 69. INDIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. INDIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. INDIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. INDIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 73. INDONESIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. INDONESIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 75. INDONESIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. INDONESIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 77. JAPAN STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. JAPAN STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 79. JAPAN STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. JAPAN STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 81. MALAYSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. MALAYSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 83. MALAYSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. MALAYSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. PHILIPPINES STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. PHILIPPINES STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 87. PHILIPPINES STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. PHILIPPINES STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 89. SINGAPORE STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SINGAPORE STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 91. SINGAPORE STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. SINGAPORE STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 93. SOUTH KOREA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SOUTH KOREA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 95. SOUTH KOREA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. SOUTH KOREA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 97. TAIWAN STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TAIWAN STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 99. TAIWAN STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. TAIWAN STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 101. THAILAND STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. THAILAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 103. THAILAND STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. THAILAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. VIETNAM STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. VIETNAM STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 107. VIETNAM STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. VIETNAM STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 114. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. DENMARK STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 118. EGYPT STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. EGYPT STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 120. EGYPT STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. EGYPT STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 122. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 124. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. FINLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 126. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 128. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. FRANCE STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 130. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 132. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. GERMANY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 134. ISRAEL STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. ISRAEL STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 136. ISRAEL STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. ISRAEL STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 138. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 140. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. ITALY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 142. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 144. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NETHERLANDS STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. NIGERIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. NIGERIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 148. NIGERIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. NIGERIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 150. NORWAY STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. NORWAY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 152. NORWAY STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. NORWAY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 154. POLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. POLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 156. POLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. POLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 158. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 160. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. QATAR STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 162. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 164. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. RUSSIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 166. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 168. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SAUDI ARABIA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH AFRICA STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 174. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 176. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SPAIN STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 178. SWEDEN STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. SWEDEN STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 180. SWEDEN STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SWEDEN STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 182. SWITZERLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. SWITZERLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 184. SWITZERLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. SWITZERLAND STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 186. TURKEY STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. TURKEY STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 188. TURKEY STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. TURKEY STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 193. UNITED ARAB EMIRATES STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 194. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 196. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. UNITED KINGDOM STERILE INJECTABLE DRUGS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 198. STERILE INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 199. STERILE INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2023